Üç farklı speküler mikroskopi cihazı ile ölçülen korneal endotel parametrelerinin karşılaştırılması: Karşılaştırmalı klinik çalışma

ABS TRACT Objective: The present study aimed to compare the Nidek CEM-530 (Nidek Co., Japan), Konan CellChek XL (Konan Medical, Hyogo, Japan), and Topcon SP-3000P (Topcon Corporation, Tokyo, Japan) noncontact specular microscopes (NCSM) in terms of endothelial cell density (ECD), morphological endothelial cell parameters, and central corneal thickness (CCT), in healthy subjects. Material and Methods: Right eyes of 49 patients were included in this study. ECD, CCT, average cell area, coefficient of variation, standard deviation of cell area, cell hexagonality ratio were evaluated with Nidek CEM-530, Topcon SP-3000P and The CellChek XL NCSMs. Results: The mean age was 36.2±9.6 years. The mean ECD was 2809±24.1, 2626±50.4, and 2588±32.1 in measurements with Konan CellCheck XL, Topcon SP-3000P, and Nidek CEM-530 NCSMs, respectively. The difference was statistically significant between Konan CellCheck XL with Nidek CEM-530 and Topcon SP-3000P (p<0.001 for both). The hexagonality ratio results between these 3 devices were statisti cally significant in all paired comparisons (p<0.001, for all). The mean CCT was 534.4±5.0, 553.9±5.6, 567.5±5.3 in measurements with Nidek CEM-530, Konan CellCheck XL, and Topcon SP-3000P, respectively. CCT values obtained with Topcon SP-3000P were found to be higher than with other devices (p<0.001, for both). Conclusion: Among the 3 devices, the highest ECD values were obtained with Konan CellCheck XL and the highest CCT values were obtained with Topcon SP-3000P. On account of the discrepancies in endothelial pa rameters tested in our study, we do not advise using these devices in terchangeably.Amaç: Bu çalışmada, sağlıklı kişilerde Nidek CEM-530 (Nidek Co., Japonya), Konan CellChek XL (Konan Medical, Hyogo, Japonya) ve Topcon SP-3000P (Topcon Corporation, Tokyo, Japonya) temassız speküler mikroskopların [noncontact specular microscopes (NCSM)] endotel hücre yoğunluğu (EHY), morfolojik endotel hücre parametre leri ve santral kornea kalınlığı (SKK) açısından karşılaştırılması amaçlanmıştır. Gereç ve Yöntemler: Bu çalışmaya, 49 hastanın sağ gözü dâhil edildi. EHY, SKK, ortalama hücre alanı, varyasyon katsayısı, hücre alanının standart sapması, hekzagonal hücre oranı, Nidek CEM530, Topcon SP-3000P ve CellChek XL temassız speküler mikroskop cihazları incelendi. Bulgular: Ortalama yaş 36,2±9,6 yıl idi. Konan CellCheck XL, Topcon SP-3000P ve Nidek CEM-530 NCSM’lerle yapılan ölçümlerde ortalama EHY sırasıyla 2809±24,1, 2626±50,4 ve 2588±32,1 idi. Konan CellCheck XL ile Nidek CEM-530 ve Topcon SP-3000P ölçümleri arasındaki fark istatistiksel olarak anlamlıydı (her ikisi için p<0,001). Bu 3 cihaz arasındaki hekzagonal hücre oranı sonuçları, tüm ikili karşılaştırmalarda istatistiksel olarak anlamlıydı (tümü için p<0,001). Nidek CEM-530, Konan CellCheck XL ve Topcon SP-3000P ölçümlerinde ortalama SKK sırasıyla 534,4±5,0, 553,9±5,6, 567,5±5,3 idi. Topcon SP-3000P ile elde edilen SKK değerleri diğer cihazlara göre daha yüksek bulundu (her ikisi için p<0,001). Sonuç: Üç cihaz arasında en yüksek EHY değerleri Konan CellCheck XL ile, en yüksek SKK değerleri ise Topcon SP-3000P ile elde edildi. Çalışmamızda test edilen endotelyal parametrelerdeki farklılıklar nedeniyle bu cihazların birbirinin yerine kullanılmasını önermiyoruz

Usher syndrome associated with Fuchs’ heterochromic uveitis: a case report

We report a case of Usher syndrome in association with unilateral Fuchs’ heterochromic uveitis

An unilateral acute ıdiopathic maculopathy case: masquerading as hereditary maculopathy

İstanbul Bilim Üniversitesi, Tıp Fakültesi.Sağ gözünde iki haftadır devam eden az görme şikayeti bulunan 15 yaşında erkek hasta kliniğimize başvurdu. Hastaya başka bir merkezde herediter makülopati tanısı konulduğu öğrenildi. Sağ gözünün görmesi 2/10 olan hastaya FFA, OKT ve multifokal ERG sonrasında unilateral akut idiyopatik makülopati tanısı konuldu. Hastanın görme keskinliği 5 hafta sonra tedavisiz 10/10 tespit edildi.A 15-year-old male patient presented to our clinic with loss of central vision that began about 2 weeks before presentation. He diagnosed with hereditary maculopathy in another clinic. His visual acuity was 2/10. After he underwent FFA, OKT and multifocal ERG, he diagnosed as unilateral acute idiopathic maculopathy. His visual acuity recovered to 10/10 by the end of 5 weeks

Intravitreal dexamethasone implant results in the treatment of non-infectious uveitis

Objective: The objective of this study was to evaluate the efficacy of intravitreal dexamethasone implant in non-infectious uveitic macular edema. Methods: Between April 2013 and February 2017, 27 eyes of 21 patients were included in the study at Haydarpasa Numune Training and Research Hospital. The files of patients who underwent intravitreal dexamethasone implantation for non-infectious uveitic macular edema and followed up at least 6 months were retrospectively reviewed. The patients were evaluated in terms of best-corrected visual acuity (BCVA) and central macular thickness (CMT) before and at the 1st, 3rd, and 6th months after injection and the need for re-injection. Results: Twenty-seven eyes of 21 patients were included in the study. The mean age of the patients was 39.2±11.7 years. The mean monitoring time was 24.15±10.08 months. In patients who received single-dose intravitreal dexamethasone implant, the decrease in CMT measurements and improvement in BCVA measurements at 1, 3, and 6 months after injection compared to baseline was found to be statistically significant (p=0.001 for each). Recurrence was detected in 33.3% (n=9) of the cases during follow-up; in cases with recurrence, second implants were repeated after an average of 9.67±3.12 months. The third dexamethasone implantation was applied due to the second relapse of four cases from nine relapsing cases. Third implants were performed at an average of 12.50±4.79 months. During the follow-up period, the most common complications in our patients were cataract (37%) and increased intraocular pressure (40.7%). Conclusion: Intravitreal dexamethasone implantation is an effective and reliable treatment option in non-infectious uveitic macular edema. There was no difference between the first dose and re-implantations in terms of efficacy and safety